Research Article |
|
Corresponding author: Daniela Simona Cavalu ( simona.cavalu@gmail.com ) Academic editor: Mariyana Atanasova
© 2026 Catalina Danila, Lucian Faur, Lucian Mocan, Daniela Simona Cavalu.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Danila C, Faur L, Mocan L, Cavalu DS (2026) Comparative molecular docking and ADMET profiling of niclosamide and berberine against multiple Helicobacter pylori enzymatic targets. Pharmacia 73: e212118. https://doi.org/10.3897/pharmacia.73.e212118
|
Objectives: The eradication of Helicobacter pylori is often challenged by antimicrobial resistance, adherence issues, and regional variation in treatment outcomes. As a hypothesis-generating step, early-stage pharmaceutical prioritization can identify repurposed or bioactive structures for experimental testing. This study compared the docking profiles of niclosamide and berberine against selected H. pylori enzymatic targets, using levofloxacin as a clinically relevant antibacterial comparator.
Materials and methods: Blind molecular docking was performed against H. pylori urease, DNA gyrase subunit A, and shikimate kinase. Top-ranked poses were described using Vina-type scores, three-dimensional binding inspection, two-dimensional residue-interaction mapping, and absorption, distribution, metabolism, excretion, and toxicity (ADMET)/drug-likeness predictions. Docking scores were treated as ranking scores rather than binding free energies or experimental affinity constants.
Results: In this small docking matrix, berberine produced the most negative descriptive mean score, while niclosamide produced one of the two top-ranked urease poses. These score differences do not establish differences in binding affinity, target engagement, or biological potency. Levofloxacin was included as a clinically relevant comparator. Predicted ADMET descriptors highlighted compound-specific questions related to exposure, solubility, and formulation but were not interpreted as evidence of therapeutic suitability.
Conclusion: The integrated analysis prioritizes niclosamide and berberine for further anti-H. pylori investigation without demonstrating binding, enzyme inhibition, antibacterial activity, or therapeutic efficacy. The predicted poses and scores, considered alongside existing experimental literature and predicted ADMET descriptors, define testable hypotheses for urease inhibition assays, minimum inhibitory concentration (MIC) determination, cytotoxicity testing, and formulation-focused studies.
ADMET, berberine, DNA gyrase, drug repurposing, Helicobacter pylori, levofloxacin, molecular docking, niclosamide, pharmaceutical prioritization, shikimate kinase
Helicobacter pylori remain one of the most clinically important bacterial pathogens in gastroenterology because of its high global prevalence and its established association with chronic active gastritis, peptic ulcer disease, gastric mucosal atrophy, intestinal metaplasia, dysplasia, and gastric adenocarcinoma (
The biological and clinical significance of this classification is supported by prospective cohort evidence linking H. pylori infection to the subsequent development of gastric cancer, the Correa multistep model of gastric carcinogenesis, and mechanistic evidence demonstrating that bacterial virulence factors, chronic inflammation, host susceptibility, and environmental factors influence disease progression (
The Kyoto global consensus further established H. pylori gastritis as an infectious disease that should be diagnosed and treated, while meta-analytic evidence indicates that eradication therapy can reduce the subsequent risk of gastric cancer in appropriate populations (
International and regional clinical practice guidelines serve as a guide for anti-H. pylori treatment; however, there is no universal regimen applicable to all patients. The Maastricht VI/Florence Consensus Report emphasizes local antibiotic resistance patterns, prior antibiotic exposure, treatment history, and susceptibility testing when available, providing an important framework for treatment selection in Europe and other international settings (
Other recommendations, such as the Toronto Consensus and the World Gastroenterology Organization guidelines, also emphasize treatment duration, local resources, regional resistance trends, and the diminishing efficacy of empirical clarithromycin-based therapy (
The American Gastroenterological Association Clinical Practice Update cited here addresses the diagnosis and management of atrophic gastritis, including H. pylori-associated atrophic gastritis and the importance of identifying and treating the infection (
Consequently, contemporary H. pylori management relies on guideline-directed combination therapy tailored to antibiotic resistance patterns, previous treatment exposure, and, whenever available, susceptibility testing.
The pharmaceutical relevance of H. pylori is therefore not limited to classical antibiotics. In the post-resistance era, computational repurposing and early absorption, distribution, metabolism, excretion, and toxicity (ADMET)-based prioritization can help identify compounds worth testing in focused urease, minimum inhibitory concentration (MIC), synergy, cytotoxicity, and resistance-development assays.
Niclosamide was selected as a repurposed anthelmintic with reported anti-H. pylori activity and broad anti-infective interest (
The selection of niclosamide was supported by experimental data rather than docking convenience alone. In an in vitro and infection-model study, niclosamide inhibited H. pylori strain 60190 with an MIC of 0.25 µg/mL, remained active at acidic pH, showed partial synergy with metronidazole and proton pump inhibitors, reduced H. pylori adhesion/invasion of gastric epithelial cells by approximately 3 log CFU, did not generate detectable resistance after prolonged exposure, and was active in a Galleria mellonella–H. pylori infection model (
Although its mechanism and pharmacological limitations are still incompletely defined, berberine was chosen because preclinical and clinical observations point to anti-H. pylori relevance. A 14-day quadruple regimen containing berberine achieved eradication rates of 90.1% by intention-to-treat analysis and 91.3% by per-protocol analysis, according to a randomized phase IV trial, with non-inferiority to a quadruple regimen containing bismuth in the Chinese population studied (
Evidence on berberine, however, is not consistently favorable in every formulation and therapeutic setting. Rather than showing definite superiority, a randomized trial of triple therapy incorporating berberine reported similar eradication rates among the groups under investigation (
Molecular docking, ADMET profiling, virtual screening, network pharmacology, and experimental follow-up have increasingly been integrated in recent anti-H. pylori research. This body of work is relevant because it shows that computational studies can be useful when they are presented as rational early-stage prioritization rather than as evidence of clinical effectiveness. By combining residue-level interaction maps, a uniform multitarget docking matrix, literature-guided ligand selection, and pharmacokinetic interpretation, the present study follows that approach. Recent articles in Pharmacia likewise illustrate a spectrum of computational workflows, including molecular docking of ginger-derived bioactive compounds, docking-based assessment of candidate inflammatory mediators, pharmacophore-guided virtual screening with molecular dynamics, and docking followed by molecular dynamics stability analysis (
Table
Representative anti-H. pylori computational and integrated studies used to position the present pharmaceutical prioritization workflow.
| Study | Compounds/source | H. pylori target(s) or readout | Computational/experimental level | How it supports the present manuscript |
|---|---|---|---|---|
| ( |
Oroxindin, rosmarinic acid, and verbascoside, alone or combined with antibiotics | Urease, shikimate kinase, aspartate-semialdehyde dehydrogenase; MIC and checkerboard readouts | Docking, drug-likeness filtering, MIC testing, and synergy analysis | Strong precedent for using docking/drug-likeness as a rational screening step before microbiological validation of adjuvant anti-H. pylori candidates. |
| ( |
Selected phytochemicals; terpineol highlighted | H. pylori urease and whole-cell anti-H. pylori readouts | Docking, in vitro urease inhibition, MIC, and combination testing with metronidazole | Shows that urease-oriented docking can be used when linked to pharmacological interpretation and experimental follow-up. |
| ( |
Glycyrrhizin, cinnamaldehyde, and coumarin with antibiotic comparators | BabA, SabA, CagA, VacA, and urease | Molecular docking plus ADMET/drug-compatibility assessment | Recent precedent for H. pylori docking/ADMET prioritization; supports the acceptability of a computational screening format when limitations are explicit. |
| ( |
Virtual-screening hits selected as urease-inhibitor candidates | H. pylori urease | Pharmacophore/structure-based virtual screening, ADME filtering, molecular dynamics, and MM-GBSA | Higher-complexity benchmark. It clarifies that the present manuscript is broader in target scope but more preliminary because it does not include MD/MM-GBSA. |
| ( |
StreptomeDB-derived candidate molecules | DAH7PS, a shikimate-pathway protein selected from a target-discovery pipeline | Core-proteome target selection, homology modeling, AutoDock Vina docking, MD, and ADMET | Supports shikimate-pathway proteins as rational H. pylori antibacterial targets and validates target-prioritization logic. |
| ( |
Niclosamide and related anthelmintics | Whole-cell H. pylori growth and host-cell adhesion/invasion models | Experimental anti-H. pylori study, not docking-centered | Provides direct biological rationale for including niclosamide as a repurposing candidate rather than as an arbitrary docking ligand. |
| ( |
Berberine derivatives discovered through a deep-learning workflow | Drug-susceptible and drug-resistant H. pylori strains; OMP-related targets | AI-guided discovery plus microbiological, pharmacokinetic, and target-validation experiments | Supports berberine-derived scaffolds as a credible anti-H. pylori chemical space and strengthens the mechanistic interest in berberine. |
| ( |
Phenolic/flavonoid constituents of Viscum album L. | Urease and shikimate-pathway enzymes, among others | Docking plus interaction mapping and in vitro anti-urease/anti-virulence readouts | Shows that enzyme-focused H. pylori docking can be integrated with natural-product pharmaceutical exploration. |
| ( |
Fisetin, quercetin, and geniposide | H. pylori HtrA protease plus bacterial growth readouts | Docking, molecular dynamics, and experimental validation of enzyme inhibition and anti-H. pylori growth effects | Illustrates a validation pathway that future work could follow after the prioritization generated in the present study. |
| Present study | Niclosamide, berberine, and levofloxacin comparator | Urease, DNA gyrase A, and shikimate kinase | CB-Dock2/Vina docking, three-dimensional inspection, two-dimensional interaction maps, descriptive score summaries, and predicted ADMET profiling | Provides a compact comparative multitarget, hypothesis-generating framework; it does not validate binding or mechanism and requires biochemical and microbiological testing. |
Blind molecular docking, interaction mapping, and ADMET-based prioritization were combined in this in silico original research study. The procedure created a 3 × 3 descriptive docking matrix comparing three ligands across three molecular targets associated with H. pylori. The analysis was not intended to replace biochemical or microbiological validation; it was a hypothesis-generating screening phase.
Shikimate kinase, DNA gyrase subunit A, and H. pylori urease were selected to represent complementary biological functions: an essential microbial biosynthetic pathway, DNA topology, and acid adaptation and colonization, respectively. Protein Data Bank (PDB) 1E9Y was chosen for urease because of its established biological relevance and structurally defined nickel-containing architecture. PDB 1ZUH was used for shikimate kinase because it is an experimentally determined H. pylori structure. DNA gyrase subunit A was represented by the AlphaFold model linked to UniProt P48370 because a suitable experimental structure for the planned blind-docking comparison was unavailable. Biological relevance does not by itself establish druggability; accordingly, these proteins were treated as plausible test targets, and tractability was not assumed from docking alone.
Metal components important for urease stability were retained, non-essential water molecules were removed, and protein files were visually examined. This step was performed to avoid disruption of the nickel-dependent architecture of urease.
Levofloxacin, berberine, and niclosamide were the ligands under investigation. Levofloxacin was used as a comparator with established clinical significance in H. pylori rescue therapy, berberine as a naturally occurring bioactive alkaloid, and niclosamide as a repurposing candidate. Three-dimensional ligand structures were created or acquired in CB-Dock2-compatible formats and examined for structural consistency before submission. Berberine was represented in its permanent quaternary ammonium form. Alternative protonation, tautomeric, and ionization microstates were not systematically enumerated for niclosamide or levofloxacin; this preparation constraint is acknowledged because ligand state can influence predicted poses and scores.
Accordingly, the ligand panel was guided by the literature. Levofloxacin was retained only as a clinically recognized antibacterial comparator, while niclosamide and berberine were given priority because of their prior anti-H. pylori-related data. The goal of the docking experiment was not to replicate the entire clinical pharmacology of eradication therapy but rather to investigate possible enzyme-level engagement.
Because levofloxacin has been linked to bacterial topoisomerase targeting and is used in rescue anti-H. pylori regimens, it was included as a therapeutically relevant comparator. It was not used to determine the clinical superiority of the repurposed compounds and was not considered a novel candidate. Since the goal was to compare two non-classical structures with a clinically well-known antibacterial reference rather than to replicate all therapeutic classes, clarithromycin and metronidazole were excluded from the docking matrix.
All ligands were assessed across the same target set, residue-level interaction maps were created, and the best-ranked poses were visually examined in three dimensions. These consistency checks aid interpretation but do not constitute formal validation of the docking protocol. No cognate-ligand redocking, receiver operating characteristic benchmarking against known binders and nonbinders, or prospective experimental validation was performed; therefore, pose accuracy and enrichment cannot be claimed. Docking was performed using CB-Dock2, an automated blind-docking server that combines cavity detection, docking, and pose ranking (
Protein structures were identified by the PDB and UniProt identifiers reported above, and ligand structures were obtained from PubChem. CB-Dock2 (
Vina-type outputs were retained in their native scoring units and were not converted to Ki or pKi. A docking score is an empirical ranking function and is not the binding free energy, delta G binding = G complex – (G free protein + G free ligand). Docking does not determine all free-state and solvent contributions required by this thermodynamic relationship; a favorable score can therefore occur for a nonbinder. Because the matrix contained only three ligands and three targets, no inferential statistical test was used. Means and standard deviations are reported only as descriptive summaries of this specific matrix and cannot support population-level or biological inference.
Molecular weight, topological polar surface area, lipophilicity, hydrogen-bond donors and acceptors, predicted gastrointestinal absorption, blood–brain barrier permeation, Lipinski rule-of-five compliance, bioavailability score, and medicinal-chemistry alerts were obtained from SwissADME-type workflows (
The complete docking matrix is presented in Table
| Target | Structure/model | Ligand | Cavity | Vina score (kcal/mol) |
|---|---|---|---|---|
| Urease | PDB 1E9Y | Niclosamide | C1 | –8.50 |
| Urease | PDB 1E9Y | Berberine | C1 | –8.50 |
| Urease | PDB 1E9Y | Levofloxacin | C1 | –7.90 |
| DNA gyrase A | AlphaFold/UniProt P48370 | Niclosamide | C1 | –7.80 |
| DNA gyrase A | AlphaFold/UniProt P48370 | Berberine | C2 | –8.50 |
| DNA gyrase A | AlphaFold/UniProt P48370 | Levofloxacin | C3 | –7.50 |
| Shikimate kinase | PDB 1ZUH | Niclosamide | C2 | –6.90 |
| Shikimate kinase | PDB 1ZUH | Berberine | C1 | –7.30 |
| Shikimate kinase | PDB 1ZUH | Levofloxacin | C2 | –7.00 |
Across the three targets, the descriptive mean scores were –8.10 ± 0.69 kcal/mol for berberine, –7.73 ± 0.80 kcal/mol for niclosamide, and –7.47 ± 0.45 kcal/mol for levofloxacin. Descriptive target means were –8.30 ± 0.35 kcal/mol for urease, –7.93 ± 0.51 kcal/mol for DNA gyrase A, and –7.07 ± 0.21 kcal/mol for shikimate kinase. Given the 3 × 3 matrix and the non-independent target–ligand structure, inferential testing was not considered informative and was removed. Fig.
Representative three-dimensional predicted poses were included to display the orientations selected by the docking algorithm before residue-level description by two-dimensional maps. These poses are shown in Fig.
Representative three-dimensional predicted poses selected by the docking workflow. A. Niclosamide with H. pylori urease; B. Berberine with DNA gyrase subunit A; and C. berberine with shikimate kinase. The panels record modeled orientations and contacts; they do not validate binding or pose accuracy.
Main residues and interaction classes observed in the best-ranked complexes.
| Target | Ligand | Main residues | Main interaction classes |
|---|---|---|---|
| Urease | Niclosamide | VAL B:473, TYR B:475, PRO B:472, MET A:12, TYR B:474, ALA A:37, LYS B:445, PHE B:441, VAL A:33 | Conventional hydrogen bonds, hydrophobic contacts, pi-related contacts, van der Waals |
| Urease | Berberine | LEU A:13, ALA A:16, ALA A:37, VAL A:33, VAL A:36, LYS B:445, PHE B:441, TYR A:32, GLN B:471, VAL B:473, SER B:438 | Pi-alkyl, pi-sigma, hydrophobic contacts, van der Waals |
| Urease | Levofloxacin | LYS B:445, VAL A:33, ALA A:37, GLN B:471, TYR B:475, TYR B:474, TYR A:32, VAL B:473, VAL A:36, PRO B:472, LEU A:13, ALA A:16, ALA B:150, SER B:567, ILE B:568 | Hydrogen bonds, van der Waals, pi-alkyl, one unfavorable positive-positive contact |
| DNA gyrase A | Niclosamide | VAL A:702, ASN A:806, LYS A:654, TYR A:804, VAL A:651, LYS A:619 | Hydrogen bonds, pi-pi stacked, pi-sigma, alkyl and pi-alkyl |
| DNA gyrase A | Berberine | PHE A:549, PRO A:809, ILE A:546, TYR A:525, SER A:537 | Pi-pi stacked, pi-T-shaped, alkyl, pi-alkyl, carbon-hydrogen bond |
| DNA gyrase A | Levofloxacin | ASP A:91, ARG A:95, GLN A:98, SER A:115, ALA A:121, GLN A:269 | Hydrogen bonds, carbon-hydrogen, halogen, attractive charge, one unfavourable positive-positive contact |
| Shikimate kinase | Niclosamide | ASP A:31, ASP A:33, MET A:34, VAL A:44, ARG A:45, GLY A:79, THR A:78, MET A:10, SER A:15, SER A:12, GLY A:13, LYS A:14, GLY A:11, PHE A:9, ARG A:107, SER A:43 | Hydrogen bonds, carbon-hydrogen, van der Waals, alkyl, pi-alkyl, pi-anion |
| Shikimate kinase | Berberine | PHE A:129, LEU A:104, PHE A:9, ARG A:132, GLY A:80, GLY A:81 | Hydrogen bonds, pi-cation, pi-T-shaped, alkyl and pi-alkyl |
| Shikimate kinase | Levofloxacin | SER A:15, VAL A:44, ASP A:31, ASP A:33, LYS A:14, SER A:12, GLY A:11, GLY A:13 | Hydrogen bonds, attractive charge, alkyl, carbon-hydrogen, positive-positive contact |
The chosen best-ranked poses were reorganized into target-specific two-dimensional interaction maps to supplement the numerical docking matrix, the representative three-dimensional binding poses, and the residue summary in Table
Compact two-dimensional Discovery Studio Visualizer interaction maps for niclosamide, berberine, and levofloxacin docked against H. pylori urease. Panels A–C correspond to niclosamide, berberine, and levofloxacin, respectively; the maps show hydrogen-bond, hydrophobic, pi-related, and van der Waals contacts supporting the selected docking poses.
Compact two-dimensional interaction maps for niclosamide, berberine, and levofloxacin docked against H. pylori DNA gyrase A. Panels A–C correspond to niclosamide, berberine, and levofloxacin, respectively. The maps illustrate the residue-level interaction patterns supporting the selected docking poses.
Compact two-dimensional interaction maps for niclosamide, berberine, and levofloxacin docked against H. pylori shikimate kinase. Panels A–C correspond to niclosamide, berberine, and levofloxacin, respectively; the maps provide residue-level support for interpretation of the docking scores.
Overall, the interaction maps show that poses with the same Vina score may contain different predicted contact patterns. This was especially noticeable for urease, where berberine and niclosamide had different dominant interaction classes despite identical scores. The maps are descriptive visualizations of predicted poses and were not treated as independent evidence of binding or biological activity (Table
| Ligand | MW (g/mol) | TPSA (A2) | Consensus logP | GI absorption | BBB permeation | Lipinski violations | Bioavailability score | Integrated interpretation |
|---|---|---|---|---|---|---|---|---|
| Niclosamide | 282.12 | 49.33 | 3.78 | High | Yes | 0 | 0.55 | Predicted descriptors do not establish exposure or suitability. Poor solubility and limited absorption require formulation and local-exposure studies. |
| Berberine | 336.36 | 40.80 | approx. 2.8–3.0 | High | Yes/predicted possible | 0 | 0.55 | Predicted GI absorption and BBB permeation do not establish suitability; complex, formulation-dependent pharmacokinetics require experimental confirmation. |
| Levofloxacin | 361.37 | 73.32 | approx. 0.8–1.3 | High | No/limited | 0 | 0.55 | Comparator only; predicted descriptors add no evidence of efficacy or safety beyond established pharmacology and resistance data. |
Urease: All three top-ranked poses occupied the same predicted cavity region. Niclosamide and berberine produced the same score (–8.5 kcal/mol), but this numerical equality does not demonstrate equal affinity or inhibition. Berberine’s predicted pose contained mainly pi-associated and hydrophobic contacts, whereas the niclosamide pose contained hydrogen-bonding, hydrophobic, and aromatic contacts. Levofloxacin produced a score of –7.9 kcal/mol with a broad predicted residue-contact pattern.
DNA gyrase subunit A: Berberine produced the most negative score in this three-ligand comparison (–8.5 kcal/mol), with a predicted pose containing aromatic contacts involving PHE A:549 and TYR A:525. Niclosamide scored –7.8 kcal/mol and levofloxacin –7.5 kcal/mol; these differences do not establish affinity or potency. Interpretation is further limited because the receptor was not an experimentally resolved cocrystallized DNA gyrase–drug complex, and fluoroquinolone action in vivo depends on the ternary DNA–enzyme–drug context.
Shikimate kinase: Scores against shikimate kinase were less negative than those for urease and DNA gyrase A in this matrix. Berberine ranked first (–7.3 kcal/mol), followed by levofloxacin (–7.0 kcal/mol) and niclosamide (–6.9 kcal/mol), but the small differences should not be interpreted as potency differences. Shikimate kinase remains conceptually relevant because the classical shikimate biosynthetic pathway is present in many microorganisms and plants but is not encoded as a corresponding pathway in humans, making its enzymes attractive, though not automatically tractable, antimicrobial targets.
Using levofloxacin as a comparator, this work offers a pharmacologically focused in silico prioritization of niclosamide and berberine against three selected H. pylori targets. The primary outcome is the creation of a ranked shortlist for experimental validation rather than the discovery of a definitive inhibitor. This distinction is important because molecular docking analyzes the plausibility of ligand–target complementarity under simplified conditions, whereas antibacterial efficacy depends on absorption, local exposure, bacterial physiology, resistance mechanisms, and toxicity.
The current computational study should not be interpreted as suggesting an antibiotic substitute but rather in the context of guideline-directed eradication therapy. A resistance-aware strategy is supported by the Maastricht VI/Florence Consensus Report, the American College of Gastroenterology (ACG) guideline, and the American Gastroenterological Association (AGA) Clinical Practice Update. Local resistance, prior antibiotic exposure, susceptibility testing when available, appropriate duration, and adherence should all be taken into account when choosing a regimen (
Existing experimental evidence shows that niclosamide can inhibit H. pylori growth under the tested conditions, retain activity at acidic pH, affect adhesion/invasion, and show no readily detectable resistance during serial exposure experiments (
Meta-analytic and clinical data indicate that berberine-containing combination regimens may improve or achieve clinically relevant eradication outcomes in some settings (
The inclusion of urease, DNA gyrase A, and shikimate kinase was intended to cover complementary biological levels: acid adaptation and colonization, DNA replication/topology, and the classical shikimate biosynthetic pathway, which is not encoded as a corresponding pathway in humans. Recent anti-H. pylori work using natural compounds and in silico enzyme targeting supports this type of multitarget framework when computational findings are subsequently connected to biochemical or microbiological validation (
The most pharmacologically intuitive results are those for urease. All three ligands occupied a predicted urease cavity with favorable or moderate scores. Urease is a nickel-dependent virulence enzyme that is necessary for adaptation to the gastric niche. Although berberine and niclosamide had the same urease score, their interaction maps revealed distinct stabilization patterns. This observation demonstrates that equal Vina scores should not be interpreted as mechanistically identical binding modes, which supports the use of two-dimensional Discovery Studio Visualizer diagrams in the main article.
The results for DNA gyrase A need to be interpreted more cautiously. Although levofloxacin is clinically associated with bacterial topoisomerase inhibition, its actual mechanism involves the enzyme–DNA complex and quinolone resistance-determining regions. Thus, the pharmacodynamic context of fluoroquinolone action cannot be properly replicated by the isolated DNA gyrase A model. However, berberine demonstrated a favorable predicted interaction driven by hydrophobic and aromatic contacts, which is in line with the increased interest in anti-H. pylori candidates derived from berberine (
The shikimate kinase scores were less negative than those for the other targets in this matrix. The enzyme belongs to the classical shikimate pathway, which is present in many microorganisms and plants but is not encoded as a corresponding pathway in humans; this biological distinction motivates testing but does not establish tractability. The small score differences do not show that any compound inhibits shikimate kinase. For the present ligands, this target should therefore be considered a lower-priority experimental hypothesis rather than a predicted mechanism.
Predicted ADMET descriptors did not validate the docking ranking. Berberine’s quaternary cationic structure, formulation-dependent exposure, and known pharmacokinetic complexity require experimental assessment. Niclosamide’s limited solubility and exposure likewise make formulation-oriented work important; its repurposing interest arises primarily from prior experimental anti-H. pylori evidence, not from a small difference in mean docking score. Levofloxacin was used only as a clinically interpretable comparator.
From a pharmacological standpoint, the value of the analysis is the joint description of predicted poses, literature-based biological plausibility, and developability questions, not the demonstration of target engagement. Berberine had the most negative descriptive mean score, but direct translation is limited by its quaternary cationic structure and formulation-dependent exposure. Niclosamide remains a logical choice for targeted anti-H. pylori testing because of prior experimental evidence and a top-ranked urease pose, not because binding was established. Levofloxacin served as a clinical comparator rather than a lead candidate.
Initial urease-inhibition tests, broth microdilution or agar-dilution MIC testing against reference and clinical H. pylori strains, checkerboard assays using standard antibiotics, and cytotoxicity testing on gastric epithelial cell models are practical next steps. Molecular dynamics and post-docking free-energy analyses could be considered for experimentally supported complexes. The resulting pharmaceutical message is deliberately restricted: (i) docking scores provide a workflow-specific ranking, not proof of binding; (ii) interaction maps describe the residue-level contacts of predicted poses; and (iii) ADMET descriptors flag properties requiring experimental pharmacokinetic and formulation assessment. None of these outputs demonstrates therapeutic suitability.
This integrated interpretation is particularly suitable for further laboratory work, including urease inhibition assays, MIC determination against H. pylori strains, cytotoxicity screening, and, if results justify it, molecular dynamics simulations.
Integrated prioritization was expressed narratively rather than in a separate redundant table. Within this limited matrix, berberine produced the most consistent score pattern, niclosamide remained the clearest repurposing candidate for urease-focused testing because of prior experimental evidence, and levofloxacin served as a clinically useful comparator. This ordering is a pragmatic experimental-prioritization proposal and not a validated affinity or potency ranking.
Representative three-dimensional poses supplement the numerical scores by showing the orientations selected by the docking algorithm. The urease and DNA gyrase examples display geometrically plausible predicted accommodation, while the two-dimensional diagrams describe the associated modeled contacts. Visual plausibility is not validation and does not establish affinity. The combined representation is useful only as a transparent record of the hypotheses selected for future testing.
The simultaneous integration of three target classes—urease, a virulence/adaptation enzyme; DNA gyrase A, a replication-related target; and shikimate kinase, an enzyme involved in a specific metabolic pathway—is a key aspect of this work. Compared with a single-protein docking experiment, this multitarget approach provides more information and is more consistent with early-stage pharmacological prioritization. The method is especially suitable for natural and repurposed compounds, for which both biological plausibility and ADMET feasibility should be considered before investing in experiments.
Therefore, the comparative value of the manuscript does not depend on the claim that docking predicts clinical response. Using a shared target panel and a uniform ADMET interpretation, it provides an organized ranking of mechanistically plausible compounds that already have antibacterial or anti-H. pylori relevance. Using computational research to reduce the experimental search space before costly microbiological or enzymatic testing, this framework supports early-stage pharmacological screening.
This research is a preliminary, hypothesis-generating prioritization study. A docking score is an empirical score for a modeled complex, not the binding free energy. Thermodynamically, delta G binding = G complex – (G free protein + G free ligand); the present workflow does not determine the free-state, solvation, desolvation, and entropic contributions needed for that quantity. A ligand with a favorable docked-complex score may therefore still prefer solution, self-associate, or fail to bind, and virtual-screening workflows can produce substantial false-positive rates (
In this comparative in silico study, berberine produced the most consistent descriptive score pattern across H. pylori urease, DNA gyrase A, and shikimate kinase, while niclosamide combined a top-ranked urease pose with the clearest prior experimental repurposing rationale. Docking scores, three-dimensional poses, two-dimensional interaction maps, and predicted ADMET descriptors were used to prioritize hypotheses, not to demonstrate binding, target engagement, enzyme inhibition, antibacterial activity, or therapeutic efficacy. The results justify focused experimental testing of berberine and niclosamide, with conclusions restricted to prioritization for urease assays, MIC testing, cytotoxicity assessment, and formulation-oriented investigation.
The authors have declared that no competing interests exist.
The authors declared that no clinical trials were used in the present study.
The authors declared that no experiments on humans or human tissues were performed for the present study.
The authors declared that no informed consent was obtained from the humans, donors or donors’ representatives participating in the study.
The authors declared that no experiments on animals were performed for the present study.
The authors declared that no commercially available immortalised human and animal cell lines were used in the present study.
The authors accept full responsibility for the content of the manuscript, including the disclosure of any use of AI.
No AI tools were used in the preparation of this manuscript.
This study was funded by University of Oradea, Romania.
Conceptualization: C.D. and S.C.; methodology: C.D. and L.F.; manuscript writing and critical revision: C.D., S.C., L.F., and L.M.
C. Danila https://orcid.org/0000-0002-7869-8969
L. Faur https://orcid.org/0000-0002-4953-1350
L. Mocan https://orcid.org/0000-0002-7444-7978
D.S. Cavalu https://orcid.org/0000-0001-7810-8925
Docking score matrices, interaction summaries, ADMET descriptor tables, and figure files can be provided by the corresponding author upon reasonable request.